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Objective To establish a one-tube fluorogenic real-time PCR assay for routine detection of Borrelia
burgdorferi (sensu lato) DNA in various clinical specimens.
Methods A fragment of the flagellin gene sequence was amplified with the TaqMan chemistry using primers
and a probe common to Borrelia burgdorferi sensu stricto, Borrelia afzelii, Borrelia garinii and Borrelia valaisiana. A
recombinant plasmid containing the chromosomal gene coding for the flagellin protein was used as standard.
Results The specificity of the assay was documented with 48 different clinically relevant Borrelia
burgdorferi strains. No cross-reaction occurred with unrelated bacteria, viruses and fungi. At an
analytic sensitivity of 10 copies, excellent precision within runs and between runs was observed.
The potential presence of inhibitors of the Taq DNA polymerase was monitored by spiking aliquots of
each sample with a plasmid containing the target sequence. Among 56 cerebrospinal fluid samples taken
from 54 patients with clinical suspicion of neuroborreliosis, one (1.8%) tested positive for Borrelia
burgdorferi sensu lato DNA. Borrelia burgdorferi DNA was also detected in five (17.9%) of 28 synovial
fluid specimens and in one (20%) of five synovial membrane biopsies obtained from 31 patients with
arthropathies. In order to test for the absence of false-positive results, 84 samples from 83 patients
without evidence of Lyme disease were investigated. None of these samples showed measurable amounts
of Borrelia burgdorferi DNA.
Conclusion By its established features, such as speed, reliability, sensitivity, specificity, the inclusion
of carryover prevention and the monitoring of inhibitors in individual test tubes, this real-time PCR assay
has proved to be a potent tool for the detection of Borrelia burgdorferi DNA under routine conditions in
diagnostic laboratories.
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INTRODUCTION
Lyme disease is a multisystem infection caused by spirochaetes
of the genospecies complex Borrelia burgdorferi sensu lato. Infec-
tion occurs through the bite of an infected tick of the Ixodidae
family. Four Ixodes species are recognized worldwide as impor-
tant vectors of Lyme borreliosis. These are I. persulcatus and
I. ricinus in the old world, and I. pacificus and I. scapularis (dammini)
in the new world.
In Europe, at least three species are known as causative agents
of the disease: Borrelia burgdorferi sensu stricto, Borrelia garinii and
Borrelia afzelii. A fourth species, Borrelia valaisiana (group
VS116), is still under consideration in this regard. Borrelia
valaisiana has so far been associated with skin manifestations
[1] and possibly with neurologic symptoms [2].
Despite the frequent appearance of a typical rash called
erythema migrans (EM), the clinical manifestations are often
not pathognomic, and usually a diagnosis cannot be made on
clinical grounds alone. Rapid, specific and sensitive diagnosis of
Lyme disease is required in order to provide patients with
appropriate treatment.
Since the identification of Borrelia burgdorferi as the agent of
Lyme disease, numerous serologic tests have been developed [3].
Unfortunately, such tests are prone to misdiagnosis of Lyme
disease, despite the introduction of a two-step protocol includ-
ing a second test (Western blot) to confirm a positive or
indeterminate enzyme-linked immunosorbent assay (ELISA)
or immunofluorescence assay [4,5]. In particular, false-negative
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ELISA results may be recorded in patients with a diagnostic
Western blot, thus limiting the validity of this assay format [6,7].
Diagnosis of Lyme disease may be established by cultivation
of the pathogen in a special medium (Barbour, Kelly, Stoenner).
However, the sensitivity of this technique is low, ranging from
30% to 70% for culture of skin biopsy specimens [8] to less than
5% for culture of cerebrospinal fluid (CSF) [9].
During the last decade, the PCR technology has been
extensively used as an alternative diagnostic instrument for
the detection of Borrelia burgdorferi DNA in clinical specimens
[1,10–20]. In these studies, the PCR assay allowed the successful
detection of Borrelia burgdorferi DNA in blood, CSF, urine, skin
biopsy, synovial membrane and synovial fluid specimens
obtained from selected categories of patients with Lyme disease.
While those protocols illustrated the significance and use of
PCR to complement or confirm the diagnosis of Lyme disease
in research studies, their formats generally did not meet the
requirements of a routine diagnostic laboratory.
In an attempt to overcome these limitations, we have devel-
oped a one-tube fluorogenic real-time PCR assay (TaqMan) for
the detection of Borrelia burgdorferi (sensu lato) DNA in a routine
laboratory setting. The test is based on the quantitative ampli-
fication of a fragment of the chromosomal gene coding for the
flagellin protein. The potential presence of inhibitors is moni-
tored using spiked specimens. A carryover prevention step
together with the use of a closed-tube system minimize the
risk of contamination. The characteristics of the assay have been
evaluated using a large number of cultured strains as well as
clinical specimens as substrates.
MATERIALS AND METHODS
Bacterial strains
Cultures of 48 isolates of the Borrelia burgdorferi (sensu lato)
complex (12 Borrelia burgdorferi sensu stricto, 12 Borrelia afzelii,
11 Borrelia valaisiana, 13 Borrelia garinii) and 10 different un-
related Borrelia species were tested.
Clinical samples
Negative control group
Blood samples from 37 healthy blood donors and 47 samples
(one urine, 34 CSF specimens, seven synovial fluid samples, two
blood samples and three synovial membrane biopsies) from
patients with unrelated infections were used as negative controls.
Patient specimens
These comprised 56 CSF samples from 54 patients with clinical
suspicion of neuroborreliosis, and 33 samples (28 synovial fluids
and five synovial membranes) from 31 patients with arthritis of
unclear etiology.
Extraction of DNA
Total bacterial DNA was extracted from cultures and clinical
specimens using a commercial kit (QIAamp DNA Mini Kit;
Qiagen Corporation, Hilden, Germany). The supplier’s pro-
tocol (QIAamp DNA Mini Kit and QIAamp DNA Blood Mini
Kit Handbook; protocol for bacteria and tissue 01/99) was
optimized for recovery of low-copy-number DNA as follows.
Suspension cultures, CSF, blood, synovial fluid or urine were
centrifuged at 5000 g for 10 min, and the pellet was recovered in
180 mL of lysis buffer and 20 mL of proteinase K provided with
the kit. The samples were incubated at 56 8C from 1 h to
overnight. Synovial membranes were digested overnight at
56 8C in 180 mL of lysis buffer and 20 mL of proteinase K.
Bound DNA was eluted twice in a total volume of 100mL of
elution buffer. The eluate was incubated at 95 8C for 5 min and
chilled on ice until use. Ten microliters of the eluted DNA was
used as template for the PCR.
Primers and probes
The published genome sequences of seven different isolates in
the genus Borrelia burgdorferi sensu lato, Borrelia afzelii VS461
(D63365), Borrelia afzelii ACAI (X75202), Borrelia afzelii HT61
(D63366), Borrelia burgdorferi IP90 (L42885), Borrelia burgdorferi
GeHo (X15660), Borrelia burgdorferi B31 (X15661) and Borrelia
garinii HT22 (D63367), were selected from the taxonomy
browser (http://www.ncbi.nlm.nih.gov/Taxonomy/taxono-
myhome.html/), a database of the National Center of Biotech-
nology Information.
A multiple sequence alignment with Clustalw software was
done on-line (http://bioweb.pasteur.fr/seqanal/interfaces/
clustalw.html), to search for homology regions within the
flagellin gene (Figure 1). The sequence of Borrelia burgdorferi
B31 (X15661) was selected to search for primers and the
fluorogenic TaqMan probe within a region of maximal homol-
ogy using the computer program Primer Express 1.0 (Applied
Biosystems, Foster City, CA, USA).
The forward primer FlaF1A, the reverse primer FlaR1 and
the fluorogenic TaqMan probe FlaProbe1 were selected (Table 1
and Figure 1). The fluorescent dyes at the 50 and at the 30 ends of
the probe are FAM (6-carboxyfluorescein; reporter) and
TAMRA (6-carboxytetramethylrhodamine; quencher), respec-
tively (Table 1). In addition, the absence of homology of the
selected primers and the probe with unrelated sequences was
checked with BLAST search, a computer program for sequence
analysis of the NCBI (National Center of Biotechnology
Information; http://www.ncbi.nlm.nih.gov/BLAST/).
The TaqMan fluorogenic probe was synthesized by Applied
Biosystems, Weiterstadt, Germany. The primers were made at
our institution with an ABI 392 DNA/RNA Synthesizer
(Applied Biosystems, Foster City, CA, USA).
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Figure1 Multiple alignment of seven published flagellin gene sequences of Borrelia burgdorferi (sensu lato) strains.The nucleotides identical among all strains are indicatedwith asterisks in the consensus sequence.
The forward primer FlaF1A, the reverse primer FlaR1and theTaqManprobe FlaProbe1are printed inbold.The accessionnumbers (NCBI) of the flagellin gene sequences used for the comparisonare: D63365(Borrelia
afzelliiVS461), X75202(Borrelia afzelii ACAI), L42885(Borrelia burgdorferi IP90), D63367(Borrelia garinii HT22), D63366(Borrelia afzelii HT61), X15660(Borrelia burgdorferi GeHo), and X15661(Borrelia burgdorferi
B31).
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Borrelia burgdorferi quantification standard
The plasmid pB31/41-9 (a gift from Dr R. Wallich, Department
of Applied Immunology, Heidelberg, Germany), containing
the flagellin gene of Borrelia burgdorferi B31 (X16833), was used
as quantification standard. The concentration of the plasmid
pB31/41-9 was measured by UV spectrophotometry. The
plasmid stock was aliquoted at 1mg/mL and stored at
20 8C. The aliquots were used only once for a serial dilution
and generation of the standard curve.
TaqMan quantitative PCR assay
Preparation of the PCR mixture, extraction and pipetting of the
clinical samples and amplification were done in three strictly
separated laboratories, using dedicated laboratory equipment
such as positive displacement pipettes, RNase- and DNase-free
pipette tips and sterile surgical gloves.
The 50-mL PCR mixture consists of 25 mL of 2TaqMan
Universal Mastermix, 300 nM FlaF1A forward primer, 900 nM
FlaR1 reverse primer, 200 nM TaqMan probe, 5 mL of H2O and
10 mL of the extracted target DNA. Each specimen was tested in
duplicate. As amplification control and to test for the potential
presence of inhibitors, an aliquot of the extract was also spiked
with 1000 copies of the plasmid pB31/41-9. As extraction
control, 1Tris-EDTA buffer (TE buffer) spiked with 500
copies of pB31/41-9 was extracted in parallel with the clinical
specimens. Negative controls containing all PCR reaction
components with the exception of template DNA (denoted
no template control; NTC) were included after each third
sample. In order to check for contamination with potential
target DNA, two additional NTCs were pipetted in each of the
pre-PCR laboratory rooms. Following an incubation step at
50 8C for 2 min (carryover prevention step, activation of the
enzyme AmpErase (uracil-N-glycosylase, UNG)) and 10 min of
incubation at 95 8C (denaturation of AmpErase UNG, activa-
tion of AmpliTaq Gold Polymerase), the samples were sub-
mitted to amplification (95 8C for 15 s, 60 8C for 1 min, 45
cycles) in an ABI Prism 7700 Sequence Detection System using
optical tubes and caps.
Following amplification and real-time data acquisition, ana-
lysis was performed with a Macintosh computer 4400/200,
applying the Sequence Detection System software version 1.6.3.
Nucleolytic cleavage of the TaqMan fluorogenic probe during
PCR generates an increase of fluorescence that is proportional
to the amount of the PCR product present in the reaction and
may be calibrated by inclusion of serially diluted reference
samples with known target DNA copy numbers. The threshold
cycle (CT) is defined as the cycle number at which the reporter
fluorescencegeneratedbycleavageof theprobepasses a threshold
set at 10 times the standard deviation of the mean baseline from
cycle 3 to cycle 15.
RESULTS
Analytic sensitivity of theTaqMan PCR assay
The standard curve was generated with serial dilutions from 10
to 100 000 copies of the reference plasmid pB31/41-9, which
contains the flagellin gene sequence of Borrelia burgdorferi sensu
stricto (B31). A typical standard curve with a linear dynamic
range of at least four orders of magnitude is shown in Figure 2.
The correlation coefficient was routinely between 0.97 and
1.00.
Using plasmid dilutions as unknown specimens, a detection
limit below 10 plasmid copies per assay was regularly obtained.
Reproducibility of the assay
To determine the intra-assay variation, identical series of 10
assays containing 50, 500 or 5000 copies of the standard plasmid
pB31/41-9 were tested. The resulting coefficients of variation
(in percentages) were 2.36, 1.77 and 0.78 for 50, 500 and 5000
copies, respectively (Table 2). The run-to-run precision (inter-
assay variability) was tested by determination of identical copy
numbers in 10 different PCR assays performed on different days
by different people. The corresponding coefficients of variation
(in percentages) were 3.47, 2.65 and 2.43 for 50, 500 and 5000
copies, respectively (Table 2).
Specificity of theTaqMan assay for strains of the taxon Borrelia
The specificity of the assay was tested with cultures from 48
isolates of the Borrelia burgdorferi complex (Table 3).
Among them, 37 are associated with Lyme disease: 12 Borrelia
burgdorferi sensu stricto, 12 Borrelia afzelii and 13 Borrelia garinii.
Table1 Primers and the probe within the flagellin gene ofBorrelia burgdorferi (sensu lato)
Sequence (50!30) Genome positiona
Forward primer FlaF1A AGC AAA TTT AGG TGC TTT CCA A 792^813
Reverse primer FlaR1 GCA ATC ATT GCC ATT GCA GA 965^946
Probe FlaProbe1 TGC TAC AAC CTCATC TGT CAT TGT AGC ATC TTT TAT TTG 918^880
aFlagellin gene sequence of Borrelia burgdorferi (GeHo) (15660).
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Eleven isolates of the species Borrelia valaisiana, whose clinical
significance is still unresolved, were also tested.
Each of these 48 isolates was detectable (Table 3). Similar
amplification rates were observed for the different species
(Borrelia burgdorferi sensu stricto IP3,Borrelia afzeliiVS461,Borrelia
garinii VS102, Borrelia valaisiana VS 116), when using identical
amounts of extracted DNA as template (data not shown).
In order to further evaluate the specificity of the assay, 10
additional Borrelia strains (Borrelia andersonii (19952), Borrelia
bissettii (DN 127), Borrelia anserina, Borrelia coriaceae, Borrelia
hermsii, Borrelia japonica (Fi340), Borrelia parkeri, Borrelia turicatae
and two strains of the group Borrelia lusitaniae (IR345, BR41))
were tested under standard conditions using culture material as
substrate. In contrast to the 48 Borrelia burgdorferi strains, no or
only background amplification signals were recorded for species
other than Borrelia burgdorferi sensu lato (data not shown).
The possibility of cross-reactions with unrelated pathogens
which may be found in clinical specimens was assessed using
various bacteria, viruses and fungi. No signal was recorded with
Escherichia sp., Salmonella Enteritidis, Acinetobacter sp., Proteus
vulgaris, Escherichia coli O157, Neisseria meningitidis, Pseudomonas
Figure 2 Amplification plot (a)
and standard curve (b) of the
Borrelia burgdorferi quantitative
assay.
Table 2 Coefficient of variation (CV) (inpercentage) of precisionwithin run
and precision from run to run
Standard DNA copies
50 500 5000
CVwithin run 2.36 1.77 0.78
CV from run to run 3.47 2.65 2.43
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aeruginosa, Streptococcus pneumoniae, Enterococcus sp., Streptococcus
agalactiae, Listeria monocytogenes, Bacillus subtilis, Staphylococcus
saprophyticus, Candida sp., hepatitis B virus, adenovirus, human
parvovirus B19, herpes simplex virus type 1, and herpes simplex
virus type 2.
Clinical samples
Sensitivity of theTaqMan assay in clinical samples
When testing synovial fluid, CSF, blood and synovial membrane
biopsies spiked with the plasmid pB31/41-9 prior to amplifica-
Table 3 Specificity of theTaqMan assay tested with 48 isolates of the taxon Borrelia
Species Isolates Countries Biological origin
Borrelia afzelii VS461 Switzerland Ixodes ricinus
P/Sto Germany Human (skin)
Pspe Germany Human (CSF)
DK3 Denmark Human (skin)
Iper Japan Ixodes persulcatus
A100S Netherlands Human (skin)
M55 Netherlands Ixodes ricinus
ACA1 Sweden Human (skin)
UMO1 Sweden Human (skin)
VS18 Switzerland Ixodes ricinus
VS25R-OR Switzerland Apodemus flavicollis
VS42R-R Switzerland Apodemus sylvaticus
Borrelia burgdorferi B31 USA Ixodes daminii
Geho Germany Human (skin)
IP3 France Human (CSF)
IP1 France Human (CSF)
BE1 Switzerland Human (synovial fluid)
VS14 Switzerland Ixodes ricinus
VS109 Switzerland Ixodes ricinus
VS206 Switzerland Ixodes ricinus
VS423 Switzerland Ixodes ricinus
VS753 Switzerland Ixodes ricinus
MAC3EMCNY86 USA Human (skin)
13062 Yugoslavia Ixodes ricinus
Borrelia garinii 20047 France Ixodes ricinus
387 Germany Human (CSF)
P/Bi Germany Human (CSF)
FAR02 Denmark Ixodes uriae
BITS Italy Ixodes ricinus
A77C The Netherlands Human (CSF)
VS102 Switzerland Ixodes ricinus
VS307 Switzerland Ixodes ricinus
VS468 Switzerland Ixodes ricinus
VSBP Switzerland Human (CSF)
VSDA Switzerland Human (CSF)
NBS16 Sweden Ixodes ricinus
Ip89 CIS Ixodes persulcatus
Borrelia valaisiana VS116 Switzerland Ixodes ricinus
F10.8.94 Germany Ixodes ricinus
Frank Germany Ixodes ricinus
Z6.11.93 Germany Ixodes ricinus
UK UK Ixodes ricinus
AR-2 The Netherlands Ixodes ricinus
M19 The Netherlands Ixodes ricinus
M52 The Netherlands Ixodes ricinus
M57 The Netherlands Ixodes ricinus
AG1 Switzerland Ixodes ricinus
VS732 Switzerland Ixodes ricinus
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tion, a detection limit below 10 copies was regularly achieved
(data not shown).
In order to evaluate the suitability of the Borrelia burgdorferi
TaqMan assay for routine use, we tested for the presence of
Borrelia burgdorferi sensu lato DNA in 173 samples from 168
patients grouped into three categories as follows (Table 4).
Patients with neurologic symptoms
Of 56 CSF samples taken from 54 patients with clinical suspi-
cion of neuroborreliosis, only one (1.8%) tested positive with 63
copies of Borrelia burgdorferi DNA/mL CSF (Table 4). A corre-
sponding serum sample gave a negative result when tested by
PCR (data not shown).
Patients with clinical suspicion of Lyme arthritis
Among 28 synovial fluid specimens from 27 patients, five
(17.9%) contained Borrelia burgdorferi sensu lato DNA, as well
as one (20%) of five synovial membrane biopsies from four
patients (Table 4). Whereas 20–41 000 genome equivalents
were detected in the synovial fluid samples, 70 genome equiva-
lents were counted in the biopsy (Table 4). No Borrelia burgdorferi
DNA was detected in blood samples available for five of six
patients who had the bacterial genome detected in synovial fluid
or synovial membrane.
The presence of inhibitors of the Taq DNA polymerase was
assessed by spiking aliquots of 89 samples (groups A and B) with
1000 copies of the plasmid pB31/41-9 prior to amplification.
The reaction was inhibited in three (3.4%) samples. However,
the inhibitory effect was overcome by a two-fold dilution of
the extracts prior to amplification.
Negative control group
In order to test for the absence of false-positive results, 37
serum samples from 37 blood donors without evidence of
Lyme disease were investigated. None of the samples tested
in duplicate showed measurable amounts of Borrelia burgdorferi
DNA.
In addition, one urine sample, 34 CSF samples, seven
synovial fluid samples, two blood samples and three synovial
membrane biopsies from 46 patients with unrelated infections
were also tested. Borrelia burgdorferi DNA could not be detected
in any of these samples (Table 4). The presence of inhibitors of
the enzyme Taq DNA polymerase in these samples was assessed
by spiking corresponding aliquots with 1000 copies of the
standard plasmid. None of the reactions was inhibited.
DISCUSSION
The significance of PCR-based assays to complement the
clinical or serologic diagnosis of Lyme disease has so far been
widely documented [1,10–21]. However, the majority of the
published PCR protocols are not suitable for day-to-day testing
in a routine laboratory setting. Namely, complex extraction and
detection protocols or technically challenging nested-PCR
formats have often been used to ensure maximal sensitivity.
Moreover, contamination and carryover prevention measures to
minimize the risk of false-positive results or the use of internal
controls to monitor the possible occurrence of false-negative
results have not been systematically included. In addition, most
of the protocols published are not designed for quantitative
detection of Borrelia burgdorferi DNA. Quantitation of the
bacterial load in clinical samples may be helpful to monitor
treatment efficacy, to gain some insight into the pathogenesis of
the infection, and to determine whether a correlation does exist
between clinical symptoms and the amount of bacteria
detected. Quantitative detection of Borrelia burgdorferi DNA
has been recently documented in mouse tissue samples using
the LightCycler technology and SYBR green as double-
Table 4 Detection and quantitation of Borrelia burgdorferi (sensu lato) DNA in patients and controls
Study group Specimen Number of patients Number of samples Positive (%) Amount DNAa Negative (%)
A CSF 54 56 1 (1.8) 63 55 (98.2)
B Synovial fluid 27 28 5 (17.9) 41000
25300
5800
100
20
23 (82.1)
Synovial biopsies 4 5 1 (20) 70 4 (80)
C Blood 39 39 0 (0) 39 (100)
Synovial fluid 7 7 0 (0) 7 (100)
CSF 33 34 0 (0) 34 (100)
Synovial biopsies 3 3 0 (0) 3 (100)
Urine 1 1 0 (0) 1 (100)
A, patients with clinical suspicion of neuroborreliosis; B, patients with unclear arthritis; C, negative controls (blood donors and patients without clinical suspi-
cion of Lyme disease).
aNumber of DNA copies per milliliter or biopsy.
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stranded DNA dye [22] or a microtiter-based competitive PCR
assay [23]. A real-time PCR assay for the quantitative detection
of Borrelia burgdorferi has been recently reported by Pahl et al.
[24]. These authors used a mouse model of Lyme disease to
evaluate the usefulness of their assay for the detection of Borrelia
burgdorferi DNA in tissue samples. However, the system was not
evaluated in a routine diagnostic setting with human clinical
specimens. TaqMan PCR has also been used to detect Borrelia
burgdorferi DNA in ticks [25] and in canine skin punch biopsy
and blood samples [26].
Taking into account the specific diagnostic parameters and
demands of a clinical laboratory setting, we have developed a
quantitative TaqMan PCR assay which allows the detection of
the clinically relevant strains within the Borrelia burgdorferi sensu
lato complex. In contrast to other protocols published pre-
viously, the ability of our assay to detect Borrelia burgdorferi sensu
lato was documented with the successful amplification of a large
number of strains. Namely, each one of the 12 Borrelia burgdorferi
sensu stricto, 12 Borrelia afzelii and 13 Borrelia garinii isolates
investigated tested positive. In addition, 11 Borrelia valaisiana
isolates were also detected with the same sensitivity. This
observation is of particular interest, because Borrelia valaisiana
(group VS116) has previously been detected in skin biopsies of
patients with EM [1], and the possible involvement of Borrelia
valaisiana has recently been suggested for patients presenting
with chronic clinical manifestations [2]. The ability of our test
to detect Borrelia valaisiana may therefore aid in the investigation
of the clinical role of this novel species.
The simple and reliable DNA extraction method combined
with the highly sensitive PCR assay and the absence of post-
amplification steps allowed us to perform the assay and to report
the results within one working day. Hence, the main features of
the assay format, such as robustness, speed and convenience,
were of high utility in routine diagnosis. In addition, the
precision and reproducibility of the assay may become impor-
tant factors in monitoring disease progression and therapeutic
efficacy, particularly in patients with chronic disease, when the
measurement of bacterial load in multiple follow-up samples
requires a constant baseline. The choice of a closed-tube system,
together with the use of the enzyme uracil-N-glycosylase and
strict dedication of equipment, efficiently contributed to the
avoidance of any detectable contamination or carryover during
an 8-month evaluation of the test under routine conditions
(data not shown). Hence, the risk of contamination leading to
false-positive PCR results, which is a major problem associated
with other PCR assay formats, is very well controlled in our
case. In addition, the presented format included monitoring for
the potential presence of inhibitors possibly causing false-nega-
tive results, a major advantage in achieving sound validity of
diagnostic results.
The applicability of the TaqMan assay to detect Borrelia
burgdorferi DNA in a routine setting was assessed with unselected
clinical samples sent to our diagnostic laboratory. These samples
were not obtained from a population of patients with confirmed
Lyme disease but from patients with anamnestic or clinical
suspicion of infection with Borrelia burgdorferi only. Of the 56
CSF samples from 54 patients with neurologic symptoms, only
one (1.8%) tested positive. A possible explanation for this low
positive rate might be very low levels of organisms present
[13,21] and/or the small volumes of CSF generally available for
the extraction. Thus, and despite its high sensitivity, PCR
analysis of CSF may not be useful to substantiate a clinical
suspicion of neuroborreliosis. Indeed, in a study where none of
471 CSF specimens submitted for Borrelia burgdorferi detection
were PCR positive, Tang et al. [27] recently suggested that
PCR of CSF is not suitable as screening test for the diagnosis of
Lyme neuroborreliosis.
In contrast, the detection of Borrelia burgdorferi DNA in
synovial fluid and in synovial membrane specimens obtained
from patients with rheumatologic manifestations illustrates
the usefulness of our PCR assay to confirm the diagnosis of
Lyme arthritis. Quantitative measurement of the bacterial
burden might be particularly useful in the case of patients
with persistent or chronic infections [12,24,28]. Namely,
detection of Borrelia burgdorferi DNA in the synovial fluid has
been reported in a 12-year-old patient with an onset of Lyme
arthritis 5 years after EM [29]. In addition, the quantitative PCR
assay may help us to monitor the elimination of Borrelia
burgdorferi DNA following antibiotic treatment. This might,
for instance, be useful for patients with treatment-resistant
Lyme arthritis who may have intra-articular persistence of
Borrelia burgdorferi DNA in synovial membrane [30]. However,
PCR results for Borrelia burgdorferi DNA may be negative
in synovial specimens obtained from patients with antibiotic
treatment-resistant Lyme arthritis and persistent synovial
inflammation [31].
Specific clinical studies aimed at establishing the diagnostic
significance of the present real-time PCR assay among con-
ventional laboratory diagnostic tools need to be conducted.
In summary, we have established a TaqMan PCR assay for the
quantitative detection of Borrelia burgdorferi sensu lato DNA in
routine laboratory practice. This assay may become a valuable
tool to complement the standard serology and to strengthen the
diagnosis of Lyme disease. In addition, the quantitative TaqMan
PCR assay for Borrelia burgdorferi sensu lato may prove to be
useful to monitor disease progression and response to antibiotic
treatment.
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